Printer Friendly

Nutriband to Acquire Carmel Biosciences in Deal Valued at USD 3.8m.

M2 EQUITYBITES-June 18, 2018-Nutriband to Acquire Carmel Biosciences in Deal Valued at USD 3.8m


18 June 2018 - Florida, US-based pharmaceutical company Nutriband Inc. (OTCQB: NTRB) has signed a letter of intent to acquire 100% of pharmaceutical company Carmel Biosciences, in a deal valued at USD 3.8m, the company said.

Nutriband said it plans to complete the deal through payment of 450,000 restricted common shares of the company's stock.

In December 2017, Carmel Biosciences received FDA approval for PREXXARTAN, the first and only approved oral liquid dosage form of the angiotensin receptor blocker valsartan in the United States.

Nutriband Inc. is a unique, result's driven, health and pharmaceutical company based around the science of transdermal/topical technologies.

Carmel Biosciences addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 18, 2018
Previous Article:Optimas Acquires US Hardware Supplier Circle Bolt/Nut.
Next Article:INTL FCStone to Acquire Luxembourg Interdealer Broker Carl Kliem.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |